The FDA announced that it issued emergency use authorization (EUA) for monoclonal antibodies developed by Eli Lilly (NYSE:LLY) for treating COVID-19.
Eli Lilly’s bamlanivimab and etesevimab received authorization to be administered together for treating mild to moderate COVID-19 in adults and pediatric patients over 12 years old and weighing at least 40 kilograms (about 88 pounds), according to a news release. Bamlanivimab had already received an EUA in November 2020 for treating mild-to-moderate COVID-19 cases.
Get the full story at our sister site, Drug Discovery & Development.